Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Contrave Is Given New Life as FDA Reverses its Position on Design of Cardiovacular Outcomes Trial (OREX, $2.45)

Investment Opinion
Orexigenís (OREX) anti-obesity drug Contrave has been given new life as the FDA reversed a previous position that would…
Read more…

Orexigen Revisited: Chances for Contrave Approval Seem Slim (OREX, $1.37)

Orexigen reported second quarter results on August 8, 2011 in a press release, but did not hold a conference call.…
Read more…

Orexigen Therapeutics (OREX)

The FDA has shown great reluctance to approve three anti-obesity agents under development: Orexigenís Contrave, Vivus Qnexa and Arenaís Lorques.…
Read more…

Orexigen Receives Crushing News That FDA Will Require Extremely Large Cardiovascular Outcomes Study In Order for Contrave To Gain Approval (OREX, $1.83)

Stock Opinion
The FDA has shown great reluctance to approve three anti-obesity agents under development: Orexigenís ($2.11, OREX) Contrave, Vivusí ($8.17,…
Read more…

Company Reports Success in Four Phase III Trials (OREX, $4.23)

Orexigen has just reported success in four phase III trials for Contrave in obesity.

Contrave Overview
The key efficacy measure in these…
Read more…

Going Over the Outlook with the New CEO, Mike Narachi (OREX, $5.32)

I have met numerous times with CFO, Graham Cooper. This was an opportunity to meet with the new CEO, Michael…
Read more…

Thoughts on Upcoming Advisory Meeting on Contrave (OREX, $5.40)

On December 3, 2010, an FDA advisory panel will review the NDA submitted by Orexigen Therapeutics for its new anti-obesity…
Read more…